Immunisation schedule of the Spanish Association of Paediatrics: 2013 Recommendations;Calendario de vacunaciones de la Asociación Española de Pediatría: recomendaciones 2013

Anales de Pediatria

Volumn 78, Issue 1, 2013, Pages

  Moreno Perez D ^a   Alvarez Garcia F J ^a   Aristegui Fernandez J ^a   Barrio Corrales, F ^a   Cilleruelo Ortega, M J ^a   Corretger Rauet, J M ^a   Gonzalez Hachero J ^a   Hernandez Sampelayo Matos T ^a   Merino Moina M ^a   Ortigosa Del Castillo, L ^a   Ruiz Contreras, J ^a  

^a NONE

Author keywords

Catch up immunisation schedules; Immunisation schedule; Vaccine preventable diseases; Vaccines

Indexed keywords

CHICKENPOX VACCINE; HEPATITIS A VACCINE; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE; ROTAVIRUS VACCINE; WART VIRUS VACCINE;

ARTICLE; CHICKENPOX; HEPATITIS A; HUMAN; IMMUNIZATION; INFLUENZA; NATIONAL HEALTH ORGANIZATION; PAPILLOMAVIRUS INFECTION; PEDIATRICS; PNEUMOCOCCAL INFECTION; ROTAVIRUS INFECTION; SPAIN;

ADOLESCENT; CHICKENPOX VACCINE; CHILD; CHILD, PRESCHOOL; HEPATITIS A VACCINES; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INFLUENZA VACCINES; MEASLES-MUMPS-RUBELLA VACCINE; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP C; PAPILLOMAVIRUS VACCINES; PNEUMOCOCCAL VACCINES; ROTAVIRUS VACCINES; VACCINATION;

EID: 84872309821     PISSN: 16954033     EISSN: 16959531     Source Type: Journal    
DOI: 10.1016/j.anpedi.2012.10.002     Document Type: Article

References (165)

1. D. Moreno-Pérez, F. Álvarez García, J. Arístegui-Fernández, F. Barrio-Corrales, M.J. Cilleruelo Ortega, and J.M. Corretger-Rauet Calendario de vacunaciones de la Asociación Española de Pediatría: recomendaciones 2012 An Pediatr (Barc) 76 2012 42.e21 42.e23
2. Calendarios de vacunación de las ciudades y comunidades autónomas españolas [consultado 30 Sept 2012]. Disponible en: http://www.aepap.org/vacunas/calendarios-espanoles
3. Centers for Disease Control and Prevention Recommended immunization schedules for persons aged 0 through 18 years-United States, 2012 MMWR 61 2012 1 4
4. Centers for Disease Control and Prevention (CDC) A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP); Part 1: Immunization of infants, children, and adolescents MMWR 54 RR16 2005 1 33
5. Centers for Disease Control and Prevention General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) [consultado 30 Sept 2012] MMWR 60 RR02 2011 1 60 Disponible en: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm?s-cid=rr6002a1-w
6. Y.H. Ni, M.H. Chang, J.F. Wu, H.Y. Hsu, H.L. Chen, and D.S. Chen Minimization of HBV infection by a 25-year universal vaccination program J Hepatol 57 2012 730 735
7. S. Dhillon DTPa-HBV-IPV/Hib vaccine (Infanrix Hexa™). A review of its use as primary and booster vaccination Drugs 70 2010 1021 1058
8. E.S. Bar-On, E. Goldber, S. Hellmann, and L. Leibovici Combined DTP-HBV-HIV vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenza B (HIB) [consultado 30 Sept 2012] Cochrane Database of Systematic Reviews 2012 Disponible en: http://onlinelibrary.wiley.com/doi/10. 1002/14651858.CD005530.pub3/pdf
9. D. Floret Comité technique des vaccinations Haut Conseil de la santé publique. Le calendrier des vaccinations et les recommandations vaccinales 2012 selon l'avis du haut Conseil de la santé publique BEH 14-15 2012 161 187
10. Ponencia de Programa y Registro de vacunaciones 4 de febrero del 2010. Propuesta de recomendación para la sustitución de la vacuna DTPa, como quinta dosis por una vacuna dTpa en el calendario de vacunación infantil recomendado por el CISNS. Documento interno de 16 de febrero del 2010 [consultado 30 Sept 2012]. Disponible en: http://www.aragon.es/estaticos/ GobiernoAragon/Departamentos/SaludConsumo/Profesionales/13-SaludPublica/ 20-Programas-Salud/Propuesta-recomendacion-sustitucion-vacuna-DTPa.pdf
11. Centers for Disease Control and Prevention Preventing tetanus, diphteria, and pertussis among adults: Use of tetanus toxoid, reduced diphteria toxoid and acellular pertussis vaccine MMRW 55 RR17 2006 1 36
12. Organización Mundial de la Salud. Calendarios del mundo [consultado 30 Sept 2012]. Disponible en: http://apps.who.int/immunization- monitoring/en/globalsummary/ScheduleSelect.cfm
13. ECDC. Pertussis vaccination overview in European countries [consultado 30 Sept 2012]. Disponible en: http://ecdc.europa.eu/en/activities/surveillance/ euvac/schedules/Pages/pertussis-schedule.aspx
14. N.P. Klein, J. Bartlett, A. Rowhani-Rahbar, B. Fireman, and R. Baxter Waning protection after fifth dose of acellular pertussis vaccine in children N Engl J Med 367 2012 1012 1019
15. Ministerio de Sanidad y Consumo. Vacunación en adultos. Recomendaciones vacuna de la difteria y tétanos. Actualización 2009 [consultado 30 Sept 2012]. 2009. Documento aprobado por la Dirección General de Salud Pública. 18 de Febrero del 2009. Disponible en: http://www.msc.es/ciudadanos/proteccionSalud/vacunaciones/docs/ TetanosDifteria-2009.pdf (último acceso).
16. European Centre for Diseases Prevention and Control ECDC Guidance. Scientific panel on childhood immunization schedule: diphteria-tetanus-pertusis (DTP) vaccination 2009 ECDC Stockholm p. 1-34
17. F. Zepp, U. Heininger, J. Mertsola, E. Bernatowska, N. Guiso, and J. Roord Rational pertusis booster vaccination throughout life in Europe Lancet Infect Dis 11 2011 557 570
18. J.D. Cherry Why do pertussis vaccines fail? Pediatrics 129 2012 968 970
19. Centers for Disease Control and Prevention Updated Recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older-Advisory Committee on Immunization Practices (ACIP), 2012 MMWR 61 2012 468 470
20. M.C. Shinall Jr., T.R. Peters, Y. Zhu, Q. Chen, and K.A. Poehling Potencial impact of acceleration of pertussis vaccine primary series for infants Pediatrics 122 2008 1021 1026
21. A.R. Foxwell, P. Mcintyre, H. Quinn, K. Roper, and M.S. Clements Severe pertussis in infants: estimated impact of first vaccine dose at 6 versus 8 weeks in Australia Pediatr Infect Dis J 30 2011 161 163
22. R. Ulloa Gutierrez Pertusis vaccination in newborns Expert Rev Vaccines 8 2009 153 157
23. C.M. Healy, M. Rench, and C.J. Baker Implementation of cocooning against pertusis in high-risk population Clin Infect Dis 52 2011 157 162
24. C. Locht, and N. Mielcarek New pertussis vaccination approaches: en route to protect newborns? FEMS Immunol Med Microbiol 2012 1 13 10.1111/j.1574-695X. 2012.00988.x
25. M. Knuf, H.J. Schmitt, J. Wolter, L. Schuerman, J.M. Jaquet, and D. Keninger Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants J Pediatr 152 2008 655 660
26. A.P. Grizas, D. Camenga, and M. Vazquez Cocooning: a concept to protect young children from infectious diseases Curr Opin Pediatr 24 2012 92 97
27. Advisory Committee on Immunization Practices (ACIP) Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged < 12 months MMWR 60 2011 1424 1426
28. th 2012 [consultado 30 Sept 2012]. Disponible en: https://www.wp.dh.gov.uk/publications/files/2012/09/CMO-Pertussis-27-09-2012- FINAL.pdf.
29. R. Booy, O. Van der Meeren, S.P. Ng, F. Celzo, G. Ramakrishnan, and J.M. Jacquet A decennial booster dose of reduced antigen content diphteria, tetanus, acellular pertusis vaccine (Boostrix™) is immunogenic and well tolerated in adults Vaccine 29 2011 45 50
30. J. Mertsola, O. Van Der Meeren, Q. He, A. Linko-Parvinen, G. Ramakrishnan, and L. Mannermaa Deccenial administration of a reduced antigen content diphteria and tetanus toxoids and acelular pertusis vaccine in young adults Clin Infect Dis 51 2010 656 662
31. T.J. Sandora, C.A. Gidengil, and G.M. Lee Pertusis vaccination for health care workers Clin Microbiol Rev 21 2008 426 434
32. Ministerio de Sanidad y Consumo. Salud Pública: Promoción de la salud y epidemiologia. Vacunación en adultos. Recomendaciones del 2004. Vacuna de la tos ferina [consultado 30 Sept 2012]. Disponible en: http://www.msc.es/profesionales/saludPublica/prevPromocion/vacunaciones/ recoVacunasAdultos.htm
33. J.D. Cherry The present and future control of pertussis Clin Infect Dis 51 2010 663 667
34. S.P. Fitzwater, J.P. Watt, G.S. Levine, and M. Santosham Haemophilus influenzae type b conjugate vaccines. Considerations for vaccination schedules and implications for developing countries Human Vaccin 6 2010 810 818
35. Centers Disease for Control and Prevention Update on vaccine-derived polioviruses-worldwide. April 2011-June 2012 MMWR 61 2012 741 746
36. Red Nacional de Vigilancia Epidemiológica. Centro Nacional de Epidemiología. Instituto de Salud Carlos III Enfermedad meningocócica en España. Análisis de la temporada 2009-2010 Bol Epidemiol Sem 19 2011 233 246
37. A. Larrauri, R. Cano, M. García, and S. De Mateo Impact and effectiveness of meningococcal conjugate vaccine following its introduction in Spain Vaccine 23 2005 4097 4100
38. Dirección General de Salud Pública y Alimentación, Consejería de Sanidad y Consumo de la Comunidad de Madrid. Infecciones que causan meningitis. 2005 [consultado 30 Sept 2012]. Disponible en: http://www.madrid.org/cs/Satellite?blobtable=MungoBlobs&blobcol= urldata&blobkey=id&blobheadervalue1=filename%3DMarzo2006. pdf&blobwhere=1158572461173&blobheadername1=Content- Disposition&ssbinary=true&blobheader=application%2Fpdf
39. Grupo de Trabajo de Enfermedad Meningocócica de la Ponencia de Programa y Registro de Vacunación. Situación actual de la enfermedad meningocócica en España. Modificación de la pauta de vacunación frente a meningococo C [consultado 30 Sept 2012]. Disponible en: http://www.msc.es/ciudadanos/proteccionSalud/infancia/docs/MenC- MARZO-2006.pdf
40. H. Campbell, R. Borrow, D. Salisbury, and E. Miller Meningococcal C conjugate vaccine: the experience in England and Wales Vaccine 27 Suppl 2 2009 B20 B29
41. H. Campbell, N. Andrews, R. Borrow, C. Trotter, and E. Miller Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity Clin Vaccine Immunol 17 2010 840 847
42. R. Borrow, N. Andrews, H. Findlow, P. Waight, J. Southern, and A. Crowley-Luke Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine Clin Vaccine Immunol 17 2010 154 159
43. A. Khatami, M.D. Snape, J. Wysocki, T.M. Jhon, S. Westcar, and N. Mesaros Persistence of antibody response following a booster dose of Hib-Menc-TT glycoconjugate vaccine to five years: a follow-up study Pediatr Infect Dis J 31 2012 1069 1073
44. D. Pace, M. Snape, S. Westcar, C. Oluwalana, L.M. Yu, and N. Begg A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddles; a phase 3 open randomised controlled trial Arch Dis Child 11 2008 963 970
45. JCVI statement on the use of meningococcal C vaccines in the routine childhood immunisation programme, 29 January 2012 [consultado 30 Sept 2012]. Disponible en: http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/ab/ JCVI/DH-094744
46. H. Christensen, M. May, L. Bowen, M. Hickman, and C.L. Trotter Meningococcal carriage by age: a systematic review and meta-analysis Lancet Infect Dis 10 2010 853 861
47. E. Miller, N. Andrews, P. Waight, H. Findlow, L. Asthon, and A. England Safety and immunogenicity of coadministering a combined meningococcal serogroup C an Haemophilus influenzae type b conjugate vaccine with 7-valent pneumococcal conjugate vaccine and measles, mumps, and rubella vaccine at 12 months of age Clin Vaccine Immunol 18 2011 367 372
48. Fichas Técnicas de Menigitec, Menjugate, NeisVac C y Menveo. Agencia Española de Medicamentos y Productos sanitarios. Ministerio de Sanidad, Servicios Sociales e Igualdad [consultado 30 Sept 2012]. Disponible en: http://vacunasaep.org/profesionales/fichas-tecnicas-vacunas/resultados? diseases=150
49. th Annual Meeting of ESPID Thesaloniki, Greece 2012
50. E. Miller, N.J. Andrews, P.A. Waight, M.P.E. Slack, and R.C. George Effectiveness of the new serotypes in 13-valent pneumococcal conjugate vaccine Vaccine 29 2011 9127 9131
51. Grupo de Trabajo Heracles (datos no publicados).
52. S.A. Madhi, P. Adrian, L. Kuwanda, W. Jassat, S. Jones, and T. Little Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine Vaccine 25 2007 2451 2457
53. M. Saaka, B.J. Okoko, R.C. Kohberger, S. Jaffar, G. Enwere, and E.E. Biney Immunogenicity and serotype-specific efficacy of a 9-valent pneumococcal conjugate vaccine (PCV-9) determined during an efficacy trial in The Gambia Vaccine 26 2008 3719 3726
54. R. Cohen, C. Levy, E. Bingen, M. Koskas, I. Nave, and E. Varon Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media Pediatr Infect Dis J 31 2012 297 301
55. S. Dagan, S. Patterson, C. Juergens, D. Greenberg, N. Givon-Lavi, and A. Gurtman Efficacy of 13-valent versus 7-valent pneumococcal conjugate vaccine (Pcv13; Pcv7) in preventing nasopharyngeal colonization: a randomized double-blind trial in Israel) 30th Annual Meeting of ESPID Thesaloniki, Greece 2012
56. J. Picazo, J. Ruiz-Contreras, J. Casado-Flores, E. Giangaspro, F. del Castillo, and T. Hernández-Sampelayo Relationship between serotypes, age, and clinical presentation of invasive pneumococcal disease in Madrid, Spain, after introduction of the 7-valent pneumococcal conjugate vaccine into the vaccination calendar Clin Vaccine Immunol 18 2011 89 94
57. J. Picazo, J. Ruiz-Contreras, B. Hernández, F. Sanz, A. Gutiérrez, and E. Cercenado Clonal and clinical profile of Streptococcus pneumoniae serotype 19A causing pediatric invasive infections: a 2-year (2007-2009) laboratory-based surveillance in Madrid Vaccine 29 2011 1770 1776
58. C. Muñoz-Almagro, C. Esteva, M. Fernández de Sevilla, L. Selva, A. Gene, and R. Pallarés Emergence of invasive pneumococcal disease caused by multidrug-resistant serotype 19A among children in Barcelona J Infect 59 2009 75 82
59. D. Tarragó, L. Aguilar, R. García, M.J. Giménez, J.J. Granizo, and A. Fenoll Evolution of clonal and susceptibility profiles of serotype 19A Streptococcus pneumoniae among invasive isolates from children in Spain, 1990 to 2008 Antimicrob Agents Chemother 55 2011 2297 2302
60. M.C. McEllistrem, and M.H. Nahm Novel pneumococcal serotypes 6C y 6D: anomaly or harbinger Clin Infect Dis 55 2012 1379 1386
61. A. Fenoll, L. Aguilar, M.J. Giménez, M.D. Vicioso, O. Robledo, and J.J. Granizo Variations in serotypes and susceptibility of adult non-invasive Streptococcus pneumoniae isolates between the periods before (May 2000-May 2001) and 10 years after (May 2010-May 2011) introduction of conjugate vaccines for child immunisation in Spain Internat J Antimicrob Agents 40 2012 18 23
62. S. Esposito, S. Tansey, A. Thompson, A. Razmpour, J. Liang, and T.R. Jones Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three dose series with routine vaccines in healthy infants and toddlers Clin Vaccine Immunol 17 2010 1017 1026
63. M.D. Snape, C.L. Klinger, E.D. Daniels, T.M. John, H. Layton, and L. Rollinson Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial Pediatr Infect Dis J 29 2010 e80 e90
64. Recommendations of the Advisory Committee on Immunization Practices (ACIP) Prevention of pneumococcal disease among infants and children-Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine MMWR 59 RR11 2010 1 18
65. Asociación Española de Pediatría. Comunicado sobre la suspensión de la financiación por parte de la Comunidad de Madrid de la vacunación frente a neumococo [consultado 30 Sept 2012]. Disponible en: http://vacunasaep.org/sala-de-prensa/comunicado-de-la-asociacion- espanola-de-pediatria-sobre-la-suspension-de-la-financiac
66. European Centre for Disease Prevention and Control (ECDC). Measles [consultado 30 Sept 2012]. Disponible en: http://ecdc.europa.eu/en/healthtopics/ measles/epidemiological-data/Pages/annual-epidemiological-reports.aspx
67. WHO Weekly epidemiological report. No. 18, 2011 [consultado 30 Sept 2012]. Disponible en: http://www.who.int/wer
68. European Centre for Disease Prevention and Control (ECDC). Surveillance Report. Measles and rubella monitoring 2012 [consultado 30 Sept 2012]. Disponible en: http://www.ecdc.europa.eu/en/publications/Publications/SUR- Monthly-measles-and-rubella-Aug-2012.pdf
69. J.A. Delgado de los Reyes, M. Arencibia-Jiménez, J.F. Navarro-Gracia, E. Alonso-Echabe, P. García-Puente, and E.M. Banqueri-Guerrero Ongoing measles outbreak in Elche, Spain, 29 January to 9 March 2012 Euro Surveill 17 2012 20119
70. E. Leuridan, N. Hens, V. Hutse, M. Ieven, M. Aerts, and P. Van Damme Early waning of maternal antibodies in era of measles elimination: longitudinal study BMJ 340 2010 e1626
71. E. Leuridan, M. Sabbeb, and P. Van Damme Measles outbreak in Europe: susceptibility of infants too young to be immunized Vaccine 30 2012 5905 5913
72. E. Leuridan, N. Goeyvaerts, N. Hens, V. Hutse, and P. Van Damme Maternal mumps antibodies in a cohort of children up to the age of 1 year Eur J Pediatr 171 2012 1167 1173
73. ECDC. EUVAC net. Calendarios europeos [consultado 30 Sept 2012]. Disponible en: http://ecdc.europa.eu/en/activities/surveillance/euvac/schedules/ Pages/schedules.aspx
74. a ed. Publicación científica y técnica, n.° 605. Washington: OMS; 2007.
75. a ed. Royal College of Paediatrics and Child Health 2011. New York: Oxford Universty Press Inc.; 2011. p. 624-7.
76. American Academy of Pediatrics Active and passive immunization L.K. Pickering Red Book; 2012 Report of the Committee on Infectious Diseases 29th ed. 2012 American Academy of Pediatrics Elk Grove Village 1 109
77. Calendario de vacunaciones del Consejo Interterritorial del Sistema Nacional de Salud 2007 [consultado 30 Sept 2012]. Disponible en: http://www.msps.es/ciudadanos/proteccionSalud/infancia/docs/c2007.pdf
78. Documento de consenso 2011 de Sociedades Científicas Españolas. Vacunación frente al virus del papiloma humano [consultado 30 Sept 2012]. Disponible en: http://vacunasaep.org/sites/ vacunasaep.org/files/VPH-Consenso-Sociedades-2011.pdf
79. Ministerio de Sanidad, Servicios Sociales e Igualdad. Gobierno de España. Coberturas de vacunación. Datos estadísticos, 2011 [consultado 30 Sept 2012]. Disponible en: http://www.msssi.gob.es/profesionales/ saludPublica/prevPromocion/vacunaciones/coberturas.htm
80. th Annual Meeting of ESPID Thesaloniki, Greece 2012
81. X. Castellsagué, T. Iftner, E. Roura, J.A. Vidart, S.K. Kjaer, F.X. Bosch CLEOPATRE Spain Study Group Prevalence and genotype distribution of human papillomavirus infection of the cervix in Spain: the CLEOPATRE study J Med Virol 84 2012 947 956
82. ® (EPAR, última actualización: 31 de julio de 2012) [consultado 30 Sept 2012]. Disponible en: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/ medicines/000703/human-med-000805.jsp&mid=WC0b01ac058001d124
83. ® (EPAR, última actualización: 30 de enero de 2012) [consultado 30 Sept 2012]. Disponible en: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/ medicines/000721/human-med-000694.jsp&mid=WC0b01ac058001d124
84. ® (FDA, última actualización: 22 de diciembre de 2010) [consultado 30 Sept 2012]. Disponible en: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm237941.htm
85. C.M. Wheeler, X. Castellsagué, S.M. Garland, A. Szarewski, J. Paavonen, P. Naud HPV PATRICIA Study Group Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial Lancet Oncol 13 2012 100 110
86. D.R. Brown, S.K. Kjaer, K. Sigurdsson, O.E. Iversen, M. Hernandez-Avila, and C.M. Wheeler The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years J Infect Dis 199 2009 926 935
87. T. Vesikari, P. Van Damme, N. Lindblad, U. Pfletschinger, D. Radley, and D. Ryan An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age Pediatr Infect Dis J 29 2010 314 318
88. C.M. Wheeler, B.M. Harvey, M.E. Pichichero, M.W. Simon, S.P. Combs, and M.M. Blatter Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trial Pediatr Infect Dis J 30 2011 e225 e234
89. C. Pedersen, M. Breindahl, N. Aggarwal, J. Berglund, G. Oroszlán, and S.A. Silfverdal Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls J Adolesc Health 50 2012 38 46
90. B. Lu, A. Kumar, X. Castellsagué, and A.R. Giuliano Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review and meta-analysis BMC Infect Dis 11 2011 13
91. L.E. Markowitz, S. Hariri, E.R. Unger, M. Saraiya, S.D. Datta, and E.F. Dunne Post-licensure monitoring of HPV vaccine in the United States Vaccine 28 2010 4731 4737
92. World Health Organization Global Advisory Committee on Vaccine Safety, report of meeting held 17-18 June 2009 Wkly Epidemiol Rec 84 2009 325 332
93. C. Chao, N.P. Klein, C.M. Velicer, L.S. Sy, J.M. Slezak, and H. Takhar Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine J Intern Med 271 2012 193 203
94. J.M. Palefsky Human papillomavirus-related disease in men: not just a women's issue J Adolesc Health 46 Suppl 4 2010 S12 S19
95. Centers for Diseases Control and Prevention (CDC) Recommendations on the use of quadrivalent human papillomavirus vaccine in males-ACIP, 2011 MMWR 60 2011 1705 1708
96. Committee on Infectious Diseases HPV vaccine recommendations Pediatrics 129 2012 602 605
97. Department of Heath and Ageing. Australian Government. National immunisation program-Human papillomavirus vaccination for boys [consultado 30 Sept 2012]. Disponible en: http://www.health.gov.au/internet/immunise/ publishing.nsf/Content/immunise-hpv
98. National Advisory Committee on Immunization (NACI) Public Health Agency of Canada. Update on human papillomavirus (HPV) vaccines [consultado 30 Sept 2012] CCDR 38 2012 ACS1. Disponible en: http://www.phac-aspc.gc.ca/publicat/ ccdr-rmtc/12vol38/acs-dcc-1/index-eng.php
99. H.W. Chesson, D.U. Ekwueme, M. Saraiya, E.F. Dunne, and L.E. Markowitz The cost-effectiveness of male HPV vaccination in the United States Vaccine 29 2011 8443 8450
100. K. Seto, F. Marra, A. Raymakers, and C.A. Marra The cost effectiveness of human papillomavirus vaccines: a systematic review Drugs 72 2012 715 743
101. Report of the Second European Expert Meeting on Rotavirus Vaccination. Vaccine. 2012;30:2237-44.
102. K. Soares-Weiser, H. Maclehose, H. Bergman, I. Ben-Aharon, S. Nagpal, and E. Goldberg Vaccines for preventing rotavirus diarrhoea: vaccines in use Cochrane Database Syst Rev 2 2012 CD008521
103. I. Ogilvie, H. Khoury, M.M. Goetghebeur, A.C. El Khoury, and C. Giaquinto Burden of community-acquired and nosocomial rotavirus gastroenteritis in the pediatric population of Western Europe: a scoping review BMC Infect Dis 12 2012 62 10.1186/1471-2334-12-62
104. B.A. Lopman, D.C. Payne, J.E. Tate, M.M. Patel, M.M. Cortese, and U.D. Parashar Post-licensure experience with rotavirus vaccination in high and middle income countries; 2006 to 2011 Curr Opin Virol 2 2012 434 442
105. R.I. Glass Unexpected benefits of rotavirus vaccination in the United States J Infect Dis 204 2012 975 977
106. P.H. Dennehy Effects of vaccine on rotavirus disease in the pediatric population Curr Opin Pediatr 24 2012 76 84
107. F. Martinón-Torres, M.B. Bouzón Alejandro, L.R. Redondo Collazo, J.M. Sánchez Lastres, S.P. Pértega Díaz, and M.T. Seoane Pillado Effectiveness of rotavirus vaccination in Spain Hum Vaccin 7 2011 757 761
108. J. Castilla, X. Beristain, V. Martínez-Artola, A. Navascués, M. García Cenoz, and N. Alvarez Effectiveness of rotavirus vaccines in preventing cases and hospitalizations due to rotavirus gastroenteritis in Navarre, Spain Vaccine 30 2012 539 543
109. ®. AEMPS, 4 noviembre del 2010 [consultado 30 Sept 2012]. Disponible en: http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/calidad/ 2010/NI-circovirus-rotateq-noviembre-2010.htm
110. Agencia Española del Medicamento y Productos Sanitarios. Informe mensual sobre medicamentos de uso humano y productos sanitarios, enero 2012. Cambios de especial interés sanitario en medicamentos ya autorizados [consultado 30 Sept 2012]. Disponible en: http://www.aemps.gob.es/informa/ informeMensual/2012/enero/docs/informe-mensual-enero-2012.pdf
111. J.P. Buttery, M.H. Danchin, K.J. Lee, J.B. Carlin, P.B. McIntyre, and E.J. Elliott Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia Vaccine 29 2011 3061 3066
112. M.M. Patel, V.R. López-Collada, M.M. Bulhões, L.H. De Oliveira, A. Bautista Márquez, and B. Flannery Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil N Engl J Med 364 2011 2283 2292
113. World Health Organization (WHO) Rotavirus vaccine and intussusception: report from an expert consultation Wkly Epidem Rec 86 2011 317 324
114. R. Desai, A.T. Curns, M.M. Patel, and U.D. Parashar Trends in intussusception-associated deaths among US infants from 1979-2007 J Pediatr 160 2012 456 460
115. I.M. Shui, J. Baggs, M. Patel, U.D. Parashar, M. Rett, and E.A. Belongia Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants JAMA 307 2012 598 604
116. J.S. Zickafoose, B.D. Benneyworth, M.P. Riebschleger, C.M. Espinosa, and M.M. Davis Hospitalizations for intussusception before and after the reintroduction of rotavirus vaccine in the United States Arch Pediatr Adolesc Med 166 2012 350 355
117. J.E. Tate, A.H. Burton, C. Boschi-Pinto, A.D. Steele, J. Duque, and U.D. Parashar 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis Lancet Infect Dis 12 2012 136 141
118. R. Desai, M.M. Cortese, M.I. Meltzer, M. Shankar, J.E. Tate, and C. Yen Potential intussusception risk versus benefits of rotavirus vaccination in the United States Pediatr Infect Dis J 32 1 2013 1 7 10.1097/INF.0b013e318270362c
119. F. Omeñaca, J. Sarlangue, L. Szenborn, M. Nogueira, P.V. Suryakiran, and I.V. Smolenov Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase iiib study Pediatr Infect Dis J 31 2012 487 493
120. S.S. Shah, S.M. Wood, X. Luan, and A.J. Ratner Decline in varicella related ambulatory visits and hospitalizations in the United States since routine inmunization against varicella Pediatr Infect Dis J 29 2010 199 204
121. M. Marin, J.X. Zhang, and J.F. Seward Near elimination of varicella deaths in the US after implementation of the vaccination program Pediatrics 128 2011 214 220
122. A. Siedler, and U. Arndt Impact of the routine varicella vaccination programme on varicella epidemiology in Germany Euro Surveill 15 2010 14 20
123. B. Tan, J. Bettinger, A. McConnell, D. Scheifele, S. Halperin, and W. Vaudry The effect of funded varicella immunization programs on varicella related hospitalizations in IMPACT centers, Canada, 2000-2008 Pediatr Infect Dis J 31 2012 956 963
124. F. Pozza, C. Piovesan, F. Russo, A. Bella, P. Pezzotti, and L. Emberti Gialloreti Impact of universal vaccination on the epidemiology of varicella in Veneto Italy Vaccine 29 2011 9480 9487
125. Comité Asesor de Vacunas de la Comunidad de Madrid. Informe sobre varicela en la Comunidad de Madrid [consultado 30 Sept 2012]. 2010. Disponible en: http://www.madrid.org
126. M. García Cenoz, J.C. Catalán, F.I. Zamarbide, M.A. Berastegui, and A.B. Gurrea Impacto de la vacunación universal frente a la varicela en Navarra, 2006-2010 An Sist Sanit Navar 34 2011 193 202
127. S.S. Chaves, P. Gargiullo, J. Zhang, R. Civen, D. Guris, and L. Mascola Loss of vaccine-induced immunity to varicella vaccine over time N Engl J Med 356 2007 1121 1129
128. S.S. Chaves, J. Zhang, R. Civen, B.M. Watson, T. Carbajal, and D. Perella Varicella disease among vaccinated persons. Clinical and epidemiological characteristics, 1997-2005 J Infect D 197 2008 S127 S131
129. L. Lu, L. Suo, J. Li, L. Zhai, Q. Zheng, and X. Pang A varicella outbreak in a school with high one-dose vaccination coverage, Beijing China Vaccine 30 2012 5094 5098
130. D.E. Michalik, S.P. Steinberg, P.S. Larussa, K.M. Edwards, P.F. Wright, and A.M. Arvin Primary vaccine failure after 1 dose of varicella vaccine in healthy children J Infect Dis 197 2008 944 949
131. M. Brisson, G. Melkonyan, M. Drolet, G. De Serres, R. Thibeault, and P. De Wals Modeling the impact of one- and two-dose varicella vaccination on the epidemiology of varicella and zoster Vaccine 28 2010 3385 3397
132. E.D. Shapiro, M. Vazquez, D. Esposito, N. Holabird, S.P. Steinberg, and J. Dziura Effectiveness of 2 doses of varicella vaccine in children J Infect Dis 203 2011 312 315
133. Centers for Disease Control and Prevention (CDC) Evolution of varicella surveillance-selected States, 2000-2010 MMWR 61 2012 609 612
134. American Academy of Pediatrics, Committee on Infectious Diseases Prevention of varicella: recommendations for use of varicella vaccines in children, including recommendations for a routine 2-dose varicella immunization schedule Pediatrics 120 2007 221 231
135. F. Zhou, I.R. Ortega-Sanchez, D. Guris, A. Shefer, T. Lieu, and J.F. Seward An economic analysis of the universal varicella vaccination program in the United States J Infect Dis 197 2008 S156 S164
136. A.J. Van Hoek, A. Melegaro, N. Gay, J. Bilcke, and W.J. Edmunds The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom Vaccine 30 2012 1225 1234
137. Consenso sobre la vacunación frente a la gripe en el personal sanitario, 2012. Documento de Consenso de Sociedades Científicas españolas [consultado 30 Sept 2012]. Disponible en: http://vacunasaep.org/ sites/vacunasaep.org/files/vac-gripe-en-p.sanitario.pdf
138. Vacunación frente a la gripe estacional en la infancia y la adolescencia. Recomendaciones del Comité Asesor de Vacunas de la Asociación Española de Pediatría (CAV-AEP) para la campaña 2012-2013 [consultado 30 Sept 2012]. Disponible en: http://vacunasaep.org/documentos
139. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2012-2013 northern hemisphere influenza season [consultado 30 Sept 2012]. Disponible en: http://www.who.int/influenza/vaccines/ virus/recommendations/201202-recommendation.pdf
140. P.L. Fraaij, and T. Heikkinen Seasonal influenza: the burden of disease in children Vaccine 29 2011 7524 7528
141. S. Esposito, C. Daleno, F. Baldanti, A. Scala, G. Campanini, and F. Taroni Viral shedding in children infected by pandemic A/H1N1/2009 influenza virus Virol J 8 2011 349
142. H. Silvennoinen, V. Peltola, R. Vainionpaa, O. Ruuskunen, and T. Heikkinen Incidence of influenza-related hospitalizations in different age groups of children in Finland: a 16-year study Pediatr Infect Dis J 30 2011 e24 e28
143. K.A. Poehling, K.M. Edwards, G.A. Weinberg, P. Szilagyi, M.A. Staat, and M.K. Iwane The underrecognized burden of influenza in young children N Engl J Med 355 2006 31 40
144. T. Jefferson, A. Rivetti, A. Harnden, C. Di Pietrantonj, and V. Demicheli Vaccines for preventing influenza in healthy children Cochrane Database Syst Rev 2008 CD004879
145. T. Heikkinen, and S. Heinonen Effectiveness and safety of influenza vaccination in children: European perspective Vaccine 29 2011 7529 7534
146. M.T. Osterholm, N.S. Kelley, A. Sommer, and E.A. Belongia Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis Lancet Infect Dis 12 2012 36 44
147. Centers for Disease Control and Prevention (CDC) Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)-United States, 2012-3 influenza season MMWR 61 2012 613 618
148. Comité Asesor de Vacunas de la Asociación Española de Pediatría. Fichas técnicas de vacunas antigripales [consultado 30 Sept 2012]. Disponible en: http://vacunasaep.org/profesionales/fichas-tecnicas- vacunas/resultados?diseases=148
149. Vacuna hepatitis A (grupos de riesgo). Circular 15/1998 de la Dirección General de Farmacia y Productos Sanitarios.
150. Comité Asesor de Vacunas de la AEP, grupo de expertos de la AEEH Recomendaciones para el uso de la vacuna de la hepatitis A en guarderías Gastroenterol Hepatol 21 1998 346 351
151. American Academy of Pediatrics Committee on Infectious Diseases Hepatitis A vaccine recommendations Pediatrics 120 2007 189 199
152. WHO position paper on hepatitis A vaccines-June 2012. Weekly Epidemiol Rec. 2012;87:261-76.
153. A. Domínguez, L. Salleras, G. Carmona, and J. Batalla Effectiveness of a mass hepatitis A vaccination program in preadolescents Vaccine 21 2003 698 701
154. A. Domínguez, M. Oviedo, G. Carmona, J.M. Jansá, E. Borrás, and L. Salleras Epidemiology of hepatitis A before and after the introduction of a universal vaccination programme in Catalonia Spain J Viral Hepat 15 suppl. 2 2008 51 56
155. A. Domínguez, M. Oviedo, G. Carmona, J. Batalla, M. Bruguera, and L. Salleras Impact and effectiveness of a mass hepatitis A vaccination programme of preadolescents seven years after introduction Vaccine 26 2008 1737 1741
156. C. Rodríguez, L. Basile, L. Urbiztondo, E. Borràs, and J. Batalla Vacunación antihepatitis A: ¿selectiva o universal? Vacunas 10 2009 4 8
157. M. Sadarangani, and A.J. Pollard Serogroup B meningococcal vaccines-an unfinished story Lancet Infect Dis 10 2010 112 124
158. A. Deasy, and R.C. Read Challenges for development of meningococcal vaccines in infants and children Expert Rev Vaccines 10 2011 335 343
159. N. Gossger, M.D. Snape, L.M. Yu, A. Finn, G. Bonna, and S. Esposito Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules. A randomized controlled trial JAMA 307 2012 573 582
160. M.E. Santolaya, M.L. O'Ryan, M.T. Valenzuela, V. Prado, R. Vergara, and A. Muñoz Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study Lancet 379 2012 617 624
161. B.D. Plykaitis, M. Stella, G. Boccadifuoco, L.M. DeTora, M. Agnus, and L. Santini Inter-laboratory standardization of the sandwich ELISA designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines Clin Vaccine Immunol 19 2012 1609 1617
162. P.C. Richmond, H.S. Marshall, M.D. Nissen, Q. Jiang, K.U. Jansen, M. Garcés-Sánchez on behalf of the 2001 Study Investigators Safety, immunogenicity and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial Lancet Infect Dis 12 2012 597 607
163. H.S. Marshall, P.C. Richmond, M.D. Nissen, Q. Jiang, A.S. Anderson, and K.U. Cansen Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18 to 36 months: a phase 1 randomized controlled clinical trial Pediatr Infect J Dis 31 2012 1061 1068
164. Centers for Disease Control and Prevention (CDC). Catch-up immunization schedule for persons aged 4 months through 18 years who start late or who are more than 1 month behind [consultado 30 Sept 2012]. Disponible en: http://www.cdc.gov/vaccines/schedules/downloads/child/catchup-schedule-pr.pdf
165. The Australian Immunisation Handbook, 9th ed, 2008. Catch-up -updated July 2009 [consultado 30 Sept 2012]. Disponible en: http://www.immunise.health. gov.au/internet/immunise/publishing.nsf/Content/handbook-catchup